Nanolynx Biologics is developing conditionally active nanobody-drug conjugates (CA-NDCs), a first-in-class therapeutic modality designed for tumor-selective activation, deep penetration, and reduced systemic toxicity. Powered by our proprietary IntelliBody™ platform, we overcome the fundamental biological and safety limitations of conventional ADCs, enabling effective targeting of hard-to-treat solid tumors. We are building a scalable pipeline in high-unmet-need oncology indications and offer partners access to next-generation CA-NDC therapeutics in a global ADC market exceeding $10B and projected to surpass $30B by 2030.
